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Abstract
Mounting evidence shows that inflammation plays a critical role in causing Alzheimer’sd i s e a s e .O v e rt h e
lastfewdecadeswehavegonefromasituationwhereinflammationwasgenerallybelievedtohavenorole
in the disease to the current picture where chronic activation of IL-1 inflammation has been shown to
account for many of the hallmarks of the disease. This review is a personal account of the quest to prove
that inflammation plays a critical role in causing Alzheimer’s disease.
Even today, Alzheimer’s is still a disease that is definitively
diagnosed only after death and autopsy, when it is easy
to recognize the disease’s cardinal features: a shrunken
brain with amyloid plaques dotted among neurons laden
with neurofibrillary tangles, and often with inclusions
similar to those found in the brains of patients who have
died of Parkinson’s. These irrefutable histological markers
of Alzheimer’s led to the logical conclusion by most resear-
chersthatplaquesarethecauseoftheproblem.Manyphar-
maceutical companies have taken vigorous aim at amyloid
with no clear evidence so far that ridding the brain of
plaquesin Alzheimer’s disease results in cognitive improve-
ment [1]. Lacking a smoking gun that definitively singles
out the plaques as the causative agent, amyloid is the
scientificequivalentofaculpritassumedguiltyuntilproven
innocent.
A secondary role for plaques in pathogenesis is not a new
idea. The first such plaques were observed by Paul Blocq
and Georges Marinesco in 1892 in the brain of a patient
with epilepsy. They suggested that the source of the
plaques was the surrounding small cells (reviewed in [2])
implying that amyloid plaques are markers left after the
occurrence of a series of events such as neuronal damage
engendered by neuronal hyperexcitability in epilepsy,
genetic variations, head trauma, and aging. In 1907,
Oskar Fischer almost immediately set aside the impor-
tance of the small cells or any other entities other than
amyloid plaques as central in Alzheimer’s pathogenesis,
and the amyloid hypothesis was accepted as the cause of
the disease [1].
A hundred years later, in the 1980s, the amyloid-plaque
hypothesis gained further ground with the sequencing of
the amyloid beta peptide in plaques and the mapping of
the gene encoding its precursor protein (APP) to chromo-
some 21. Identification of a small group of Alzheimer’s
families that carried mutations in their APP gene more or
lesssolidifiedamyloidastheimportantfacetinAlzheimer’s
pathogenesis. However, inheritance of such mutations did
n o te x p l a i nt h ev a s tm a j o r i t yo fA l z h e i m e r ’sc a s e s —the
sporadic, non-genetic cases.
My interest and those of today’s new crop of researchers
centers on the potential of Blocq and Marinesco’ss m a l l
cells comprised of microglia and astrocytes, now known to
constitute the brain’s innate immune system. I envisioned
that sources that act beneficially in limited settings, such
as glia, would in chronic situations be harmful. Seeing
Alzheimer’s pathogenesis with fresh eyes and finding that
overexpressed proinflammatory proteins are the likely
instigators of neuropathological changes, including both
plaque and tangle formation, we proposed that amyloid
plaques are more likely to be a response to the disease,
rather than its initiator, which is an idea that continues to
gain acceptance.
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My involvement with Alzheimer’s research began some-
what accidentally in 1983 when I attended a seminar on
the disease given by Roger Rosenberg at Southwestern
Medical School. At the time, I was studying the
differentiation of neurons in the developing cerebellum,
using a systemic immune disease—the graft-versus-host
response—that could be induced, and a few days later
“cured.” The immune response would temporarily halt
neuronal development, allowing me to manipulate
specific developmental events in each of the cerebellar
cell types [3-5]. Back then, prominent immunologists
believed that the immune system and the CNS were
completely independent [6], but my observations of the
developing rat brain convinced me that there was a
connection.
So when Rosenberg showed silver-stained sections from
the brains of Alzheimer’s patients— enlarged, activated
microglia and astrocytes lying among the neurons—
amyloid plaques were clearly evident. I couldn’t help
wondering if those microglia located in and around
trash-like plaques, and among neurons that had to exist
in their presence, would respond as their macrophage
counterparts do when challenged in the periphery. My
question was, would they make and release interleukin-1
(IL-1)? I bet yes.
At the time, researchers knew that microglia could act like
macrophages and served as the immune cells of the brain.
However, back in 1983, all we knew was that they re-
sembled macrophages, the peripheral immune cells that
engulf pathogens and secrete the cytokine IL-1, activating
multiple immune functions of T helper cells. By then we
knew too that the overexpression of IL-1 in arthritis led to
progressive joint deterioration [7]. I wondered whether
microglia in the brain might also overexpress IL-1 in
Alzheimer’sandleadtoneuronaldeteriorationinthebrain.
What if damaged or stressed neurons were activating
microglia to release excessive amounts of IL-1, which in
turn activated astrocytes (analogous to macrophage IL-1
activation of T helper cells) and caused them to release
S100, a soluble astrocyte cytokine known to promote
neuron survival? I tested this idea by measuring tissue
levels and cellular expressionof IL-1 and S100in brains of
patients who had succumbed to Alzheimer’sd i s e a s ea n d
in the brains of disease-free individuals. Indeed, we could
see activated glia as well as measure profuse overex-
pression of IL-1 and S100. It was the first time that a
meaningful immune response was shown in the brain. In
addition, for the first time inflammatory cytokines such as
IL-1 and S100 were associated with Alzheimer’sd i s e a s e .
These results laid the ground work for establishing
cytokines as contributors to and promoters of neurode-
generative diseases in analogy to their role as drivers in
systemic degenerative diseases.
My hypothesis was that, in the early stages, the disease
progressed via self-propagating neuronal injury or stress
driven by glial activation and cytokine release. Because
we had no way of detecting and analyzing early-stage
Alzheimer’s disease, I needed a model that would mimic
the early-onset form of the disease. For this I turned to
Down’s syndrome. Down’s with its three, rather than
the usual two, copies of bAPP was shown by Henry
Wisniewski, at the New York State Institute for Basic
Research in Developmental Disabilities, to lead to the
clinical and pathological features of Alzheimer’s by early
middle age [8]. Not only that, but Rachael Neve at
Harvard Medical School and her colleagues saw that
rather than the 1.5-fold increase in bAPP expected from
the presence of triplicate copies of the gene, brain tissue
from Down’s fetuses had 8 times that in brain from
normal fetuses [8,9].
When we examined sections from Down’s syndrome
brain, we saw that many microglia and astrocytes were
enlarged (activated) and overexpressing IL-1 and S100 in
Down’s fetuses and newborns. The appearance of these
activated glia that were overexpressing these cytokines
was present years before plaques were noted in Down’s
syndrome. These findings supported the idea that glial
activation and cytokine expression are the result of
neuronal stress, not the presence of amyloid plaques. The
neuronal stress in Down’s was assumed created by the
excess expression of bAPP due to its gene duplication
fromtrisomy21.Weenvisionedthatthestressedneurons
in both Alzheimer’s and Down’s released something that
alerted glia to their distress and their response was
activation and increased expression of cytokines. Several
years later Steve Barger showed that a fragment of bAPP,
which is secreted in excess from stressed neurons,
activates microglia and induces excess release of IL-1.
Taken together, our studies provided two firsts: the
first evidence from the brain of a productive immune
response, that is a response to a neuronal stress which
precipitates a glial response that then has a neuronal
consequence; andthefirst evidenceoftheinvolvementof
the brain’s immune response in Alzheimer’s. The more
outlandish idea that I drew from these two firsts was that
neuronalstress,withoutregardtoitsorigin,wouldelicita
cascade that involved an acute phase neuronal response
that included excess expression of bAPP, release of sAPP,
and glial activation with release of IL-1.
By carefully mapping the density of plaques in slices of
diseased brain, we discerned a pattern showing that early
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surrounded by a multitude of microglia and astrocytes
expressing IL-1 and S100. On the other hand, the denser
plaques that appear later had fewer activated glia,
suggesting that glial activation and cytokine expression
play an important role early in the disease, thus provid-
ing further evidence that cytokines could be, in fact, the
driving factor [10-12].
While reports from other labs showed that microglia
produce IL-1 for activation of astrocytes [13,14] and that
S100 is essential for neuronal development and neuronal
repair [15], few journal editors in the mid-1980s shared
my view that IL-1 and S100 were drivers of Alzheimer’s
disease progression. Although our work began in 1984, it
wasn’t published until 1989, when I met Dmitry Gold-
gaber, who was working at NIH with Carleton Gajdusek
on sequencing and mapping bAPP. I met Dmitry at a
meeting where I was reporting our findings about
Alzheimer’s and Down’s syndrome. To my surprise, he
came to the meeting to report that IL-1 induces synthesis
of bAPP in cord blood cells. This was a great stroke of luck
for both of us. His results offered molecular evidence of a
connection between IL-1 and Alzheimer’s pathogenesis,
which supported my findings about both Alzheimer’sa n d
Down’s, and our results gave his work a somewhat deeper
meaning: if this cytokine was activating the production of
bAPP in cord blood, it could be behaving similarly in the
brain.Togetherourstudiesaddedcredencetotheideathat
neuronal stress and excess inflammatory cytokine produc-
tion was a driving force in neurodegeneration and in the
production of amyloid plaques. We published our papers
back to back in 1989 [16,17].
Tying the tangles together
Though I had fully expected to return to my work on
neuronal development, our proposition that inflamma-
tory cytokines were involved in—and probably driving—
neurodegeneration was met with such vigorous criticism
that I decided to devote more time to the topic.
We followed up our initial studies by examining all of
the Alzheimer’s-related events for a connection to IL-1.
Toward this, we examined the tau protein, a constituent
of the tangles seen in Alzheimer’s, and the Parkinson’s-
associated a-synuclein (responsible for producing tangles
called Lewy bodies in that disease), both of which were
discovered to be associated with Alzheimer’s by Virginia
Lee and John Trojanowski from the University of
Pennsylvania. Tau is a protein that normally stabilizes
microtubules, but when it is hyperphosphorylated at
multiple sites, as in Alzheimer’s, it creates the tangles of
filaments,theneurofibrillarytanglesinneurons,whichare
present in an Alzheimer’s brain. The protein a-synuclein,
which forms Lewy bodies in Parkinson’s, is actually a
fragment of the APP and, though it is present in many
cells in the brain, its normal function is still debated. But
like other neuropathological changes associated with
overexpression of IL-1 in Alzheimer’s, the synthesis of
a-synuclein is also induced by IL-1.
Tostudytheinvolvementofthetauprotein,weimplanted
slow-release IL-1-containing pellets in the brains of rats
and found a twofold increase in tissue levels of total tau
mRNAcomparedto rats implanted withuntreated pellets.
But since tau does not form neurofibrillary tangles unless
hyperphosphorylated, we measured tissue and cellular
levels of the hyperphosphorylated form of tau, which is
associated with the tangles, and found it was elevated
by three fold in rats with IL-1-containing pellets. When
we looked at the activity of MAP kinase p38 (MAPK p38)
to see if it might be involved in IL-1 induction of tau
hyperphosphorylation, we found that IL-1 induces eleva-
tion of the MAPK p38 mRNA. What’s more, MAPK p38
activity was necessary for tau phosphorylation in both rats
imbalanced with IL-1 pellets and in humans. When we
stained brain sections from Alzheimer’s patients we also
saw abundant MAPK p38 in the same neurons that had
high levels of hyperphosphorylated tau protein [18]. Now
we could say that IL-1 was driving both the production of
tau protein, and its hyperphosphorylation, via IL-1
induction of a specific kinase, MAPK p38. To investigate
whether IL-1 might also play a role in Lewy body patho-
logy seen in Alzheimer’s, we tested the role of IL-1 in
a-synuclein fiber production using three systems: tissue
culture, IL-1-pellet-implanted rat brains, and brain slices
from Alzheimer’s patients. All three approaches gave the
same results, showing that IL-1 overexpression was
associated with increased production of a-synuclein [19].
George Siggins and colleagues at the Scripps Research
InstitutehadreportedthathighlevelsofIL-1might reduce
learning and neurotransmission, so we examined the
possibility that IL-1 might contribute to the decrease in
the amount of acetylcholine neurotransmitter that is seen
in Alzheimer’s patients. Toward this, we used our IL-1
pellet experimental paradigm to show that IL-1 elevated
both the levels and the activity of the enzyme acetylcho-
linesterase, which degrades acetylcholine, potentially
explaining how the cytokine might be involved in the
Alzheimer’s-related reduction of this memory-related
neurotransmitter [20].
We also investigated whether IL-1 inflammatory pathways
were triggered by neuronal damage initiated by sources
such as aging, head trauma, epilepsy, and AIDS. Indeed,
aging and each of these other conditions put those affected
at increased risk for the development of Alzheimer’sa n da l l
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As a way to explain the inexorable progress of neurode-
generative changes in conditions associated with preco-
cious development of Alzheimer’s, I began to think about
neuronal stress-induced IL-1 excess as part of a cytokine
feed-back cycle, with the initiating insult coming from a
variety of sources: a genetic predisposition (such as the
APOE e4a l l e l e– a risk factor for Alzheimer’s), repeated
injury (head trauma or epilepsy) or infection (HIV), and
aging. Although the inflammatory mechanisms probably
help to clear damaged cells in limited situations, in the
long term, if microglia are activated to produce IL-1 in a
chronic fashion, they can turn on a cycle that leads to more
neuronal damage and death: damaged neurons activate IL-
1-producing microglia which in turn activate the produc-
tion of bAPP and release of sAPP. This secreted fragment
activates microgliatoproducemore IL-1,stimulatingother
neuronal responses including tau hyperphosphorylation,
plaque formation, and alpha synuclein production.
In neuroinflammation, especially IL-1, we had a viable
suspect—and a potential therapeutic target—which every-
one seemed to be ignoring. It was recognized that in
systemic conditions, such as swollen joints, both the
swelling and the IL-1 levels were amenable to non-
steroidal anti-inflammatory drugs such as aspirin and
ibuprofen. A crucial study by John Breitner at Johns
Hopkins showed that among genetically predisposed
identical twin pairs who did not show identical patterns
of Alzheimer’s onset [20], use of nonsteroidal anti-
inflammatory drugs (NSAID) by one of the twins was
associated with a several-year delay in the onset of
Alzheimer’s [11]. This was huge. If Alzheimer’sc o u l db e
delayedforuptofiveyearsasBreitnershowed,thesocietal
and economic gains would be inestimable. Breitner’sw a s
not an isolated study; a year later, a Dutch study com-
paring a large group of Alzheimer’sp a t i e n t sw h ow e r e
taking NSAIDs for other ailments versus those who were
not showed that taking NSAIDs reduced risk or delayed
onset of Alzheimer’s disease similar to Breitner’sr e s u l t s .
These findings encouraged further epidemiological stu-
dies, and in 2008 a report from the Department of
Veterans Affairs Database showed that when data from
50,000 Alzheimer’s patients were compared to those of
200,000 control patients, taking ibuprofen for as long as
five years was associated with an almost 50% reduction in
risk for Alzheimer’s (as calculated by the overall risk per
yearoflife)[22].Thiswasfollowedbyaprospectiveclinical
trial of NSAID drugs, including naproxen and celecoxib.
However, the study was stopped after about 24 months
because of drug safety concerns. However, observations
that continued for two or more years revealed a protective
effectagainsttheonsetofAlzheimer’sdiseaseincognitively
normal participants who took naproxen [23].
Much progress has been made, some by us and a lot by
others, since the days when researchers believed that
Alzheimer’s could be understood and explained without
invokingarolefortheinnate immuneplayersin the central
nervous system—the glia and their cytokines. Not only is
there much evidence that these entities and neuroinflam-
mation play a critical role in Alzheimer’s, neuroinflamma-
tion has become a topic in its own right.
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